If you worry that drugs cause enough serious adverse reactions and side-effects even after passing through a supposed draconian approval process, you’ll be even more concerned about a subtle lobbying that could lead to a relaxation of the licensing...
A second major cancer study in the US has been discredited after data had been falsified. The news follows the revelation just a month earlier that the biggest survey on breast cancer in North Ame ...
Breast cancer patients have nothing to gain from taking tamoxifen for longer than five years, according to a new study. ...
Tamoxifen, the breast cancer drug currently in the middle of a controversy over its safety, is to carry a stronger warning in the US. New labelling on the bottle is to point out the increased risk ...
The breast cancer drug tamoxifen may cause birth defects. ...
Hopes of finding healthy women to test tamoxifen, the breast cancer drug, have taken a further blow following a new study from Scotland. ...
New evidence from the Netherlands shows that long term tamoxifen use increases the risk of endometrial cancers with a poor prognosis. ...
There is growing evidence that those proposing to prescribe the drug tamoxifen as a preventative measure to women supposedly at high risk of breast cancer are simply trading one form of the diseas ...
The breast cancer drug tamoxifen-marketed in the UK as Emblon, Noltam and Tamofen, and as Nolvadex in the US and the UK-has been enjoying some favourable press comment recently. ...
American drug regulators look like opening the floodgates on the use of the breast cancer drug tamoxifen. It is about to be licensed in the US as a preventative and there's a good chance the UK m ...
What Doctors Don't Tell You